COMBINATIONAL THERAPY OF METFORMIN AND ELLAGIC ACID REDUCES INFARCT AREA AND MYOFIBRIL DAMAGE IN ISOPROTERENOL-INDUCED MYOCARDIAL INFARCTION IN WISTAR RATS
Aisha Siddiqui, Sumit Sharma, Vasim Khan, Rustam Ekbbal, Mohd. Asif Ansari and Syed Ehtaishamul Haque*
Isoproterenol is a Î²-adrenoreceptor agonist widely used as a toxicant in preclinical cardio toxic studies. Metformin is an oral biguanide which has shown cardioprotective effect in various models of myocardial infarction. Ellagic acid is a potent antioxidant which possesses free radical scavenging and also cardioprotective properties. The cardioprotective effect of these drugs in combination, however, has not been tested so far. Hence in this study we have tried to see the combinational effect of ellagic acid and metformin in isoproterenol challenged rats. Thirty six Wistar rats were randomly divided into six groups; Normal control, Toxic control, Ellagic acid alone, Metformin alone and Ellagic acid + Metformin, respectively. Histopathology and infarct size measurement was performed to assess the potential cardioprotective role of the test drugs. Ellagic acid, metformin and their combination groups showed substantial reversal in the injury, however, the effect of combination group was found to be better than the two drugs alone.
Keywords: Ellagic acid, Metformin, Isoproterenol, Myocardial Infarction, Oxidative stress.
[Full Text Article]